中文摘要：

目的：了解Bmi-1及P16蛋白在口腔黏膜癌变过程中的表达情况,探讨Bmi-1-P16通路在口腔鳞癌发生发展中的作用及意义。方法：：正常口腔黏膜10例、上皮异常增生31例、口腔鳞癌61例的石蜡包埋组织,采用免疫组化SP法检测Bmi-1及P16表达情况,分析二者的相关性及其临床病理学意义。结果：Bmi-1在正常口腔黏膜、上皮异常增生及OSCC组织中的阳性率分别为0%、29%（9/31）和62.3%（38/61）;P16在正常、上皮异常增生及OSCC组中的阳性率分别为100%（10/10）、77.4%（24/31）和47.5%（29/61）。OSCC中Bmi-1阳性率在P16阴性组高于P16阳性组,差异有统计学意义（P〈0.05）,Spearman相关分析显示两者间具负相关关系（r=-0.414,P〈0.05）。Bmi-1阳性表达及Bmi-1高表达且P16失表达与OSCC临床分期及淋巴结转移密切相关（P〈0.05）。结论：Bmi-1过表达是口腔黏膜癌变过程中的早期事件,口腔鳞癌中Bmi-1过表达可能与P16失表达有关并与临床分期及淋巴结转移密切相关,有可能作为临床评估口腔鳞癌浸润、转移和预后的参考指标之一。

英文摘要：

Objective：To investigate the expression of Bmi-1and P16 proteins in oral precancerous lesions and oral squamous cell carcinomas（OSCC）,and elucidate their possible roles pathway in oral carcinogenesis.Methods：The tissues of 10 cases of normal oral epithelium,31 cases of different-degree epithelium dysplasia and 61 cases of OSCC with different differentiation were collected and investigated for the expression of Bmi-1and P16 proteins by using immunohistochemistry.The clinical and pathological significance of Bmi-1over-expression in oral carcinogenesis was statistically analyzed by SPSS11.5.Results：The percentages of positive staining for Bmi-1were 0%in normal oral mucosa,29%（9/31）in epithelial dysplasia and 62.3%（38/61）in OSCC,respectively.The percentages of positive staining for P16 were 100%（10/10）in normal oral mucosa,77.4%（24/31）in epithelial dysplasia and 47.5%（29/61）in OSCC,respectively.The percentage of Bmi-1over-expression with negative P16 staining in OSCC was significantly higher than that in OSCC with positive P16staining（P〈0.05）,and there was a negative correlation between the expression of Bmi-1and P16 in OSCC（r=-0.414,P〈0.05）.In addition,the over-expression of Bmi-1and low-expression of P16 were positively correlated with TNM stage and lymph node metastasis in OSCC（P〈0.05）.Conclusion：Up-regulation of Bmi-1was an early event in oral carcinogenesis,and might be caused by the down-regulation of P16 in OSCC,closely correlated with TNM stage and lymph node metastasis.Bmi-1could be used as a marker for assessing the progression and prognosis of OSCC patients.